Ani Pharmaceuticals, Inc
$1.63B- Market cap
- $1.60B
- Debt
- +$309.11M
- Cash
- −$285.59M
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ANIP stock price vs MANU: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MANU's multiple
Needs MANU P/E.
Implied fair value · at ANIP's multiple
Needs EPS (TTM), ANIP P/E.
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIP FY 2025 (ended Dec 31, 2025) · MANU FY 2025 (ended Jun 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Manchester United plc · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.57x
—
Net debt / EBITDA
Leverage against operating earnings
0.11x
—
Cash and equivalents
Liquid reserves on the balance sheet
$285.59M
$86.11M
Total debt
Interest-bearing obligations outstanding
$309.11M
—
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ANIP vs SUPN
PERRIGO Co plc
ANIP vs PRGO
Viatris Inc
ANIP vs VTRS
Organon & Co.
ANIP vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
ANIP vs TEVA
Madison Square Garden Sports Corp.
ANIP vs MSGS
Liberty Media Corp
ANIP vs FWONA
SIRIUS XM HOLDINGS INC.
ANIP vs SIRI
Live Nation Entertainment, Inc.
ANIP vs LYV
VAIL RESORTS INC
ANIP vs MTN
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.